DDrare: Database of Drug Development for Rare Diseases

Letrozole (DrugBank: Letrozole)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
81	先天性副腎皮質酵素欠損症	1
89	リンパ脈管筋腫症	1

81. 先天性副腎皮質酵素欠損症　［臨床試験数：65，薬物数：77（DrugBank：20），標的遺伝子数：11，標的パスウェイ数：65］

Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 65 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00001521 (ClinicalTrials.gov)	June 8, 1995	3/11/1999	Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia	An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia (CAH)	Drug: Flutamide;Drug: Letrozole;Drug: Hydrocortisone;Drug: Fludrocortisone	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Active, not recruiting	2 Years	18 Years	All	62	Phase 2	United States

89. リンパ脈管筋腫症　［臨床試験数：38，薬物数：42（DrugBank：19），標的遺伝子数：26，標的パスウェイ数：134］

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 38 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01353209 (ClinicalTrials.gov)	May 2011	11/5/2011	Trial of Aromatase Inhibition in Lymphangioleiomyomatosis	A TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS	Lymphangioleiomyomatosis	Drug: Letrozole;Drug: Placebo	University of Cincinnati	Department of Defense	Completed	18 Years	N/A	Female	17	Phase 2	United States